Trastuzumab without an anthracycline: better for early breast cancer

    loading  Checking for direct PDF access through Ovid

Abstract

According to the results of the second interim analysis of the phase III BCIRG 006 study, presented at the 29th San Antonio Breast Cancer Symposium (SABCS) [San Antonio, Texas, US; December 2006], trastuzumab-based chemotherapy without an anthracycline is associated with a better risk-benefit ratio than trastuzumab-based chemotherapy containing an anthracycline in women receiving adjuvant therapy for early-stage breast cancer. The combinations of docetaxel [Taxotere], carboplatin and trastuzumab, and, doxorubicin, cyclophosphamide, docetaxel and trastuzumab both significantly reduce the incidence of disease recurrence and death compared with doxorubicin, cyclophosphamide and docetaxel but the incidence of adverse events, particularly cardiotoxicity, is increased when trastuzumab is administered in combination with doxorubicin.

Related Topics

    loading  Loading Related Articles